Effect of Generic vs. Brand-Name Meropenem on Mortality in a Colombian Hospital’s Intensive Care Unit

Background The quality of antibiotics is a crucial element in successful treatment of infections. Recently, the use of generic antibiotics has caused controversy because of studies reporting clinical failure and the emergence of antibacterial resistance associated with the sustained use of generic antibiotics. The present study was designed to determine the mortality associated with the use of generic meropenem (GM) and brand-name meropenem (BNM) used to treat Gram-negative infections.